RoslinCT, Lykan Biosciences Add Six cGMP Suites to Massachusetts Facility
Expansion expected to increase global capacity by 75%.
RoslinCT and Lykan Biosciences, two contract development and manufacturing organizations (CDMOs), are adding six new cGMP processing suites to their facility in Hopkinton, Mass. The new sites bring the companies’ total to 22 overall, with 14 at the aforementioned location and another eight in Edinburgh, UK.
Ranging from 105 to 525 square feet, the new processing suites are designed to meet both US and EU regulatory requirements for clinical and commercial manufacturing. As part of the increase, an automated processing room is included and will reportedly be capable of accommodating a range of manufacturing platforms as well as allogeneic and autologous-based products.
“With this expansion, we will increase our capacity by 75% enabling us to meet the needs of a greater number of projects and their respective volume requirements,” says Patrick Lucy, president and CEO of Lykan Biosciences.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
